Skip to main content
SP5007,674.37+0.43%DOW53,277.01+0.98%NASDAQ26,180.46+0.43%BTC$77,812.00+5.53%ETH$2,513.75+7.22%GOLD$4,661.60+1.97%OIL$86.64-0.22%
Smart Investors Daily
Sign InSign Up Free
OM

NASDAQ · OMCL

Omnicell, Inc.

Healthcare · Medical - Healthcare Information Services

$35.58

Up+$0.08 (+0.23%)

Updated Aug 22, 2026, 11:57 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.01B
P/E ratio
100.65
Dividend yield
0.00%
52-week range
$31.75 – $48.06
Volume
777.12K
Avg. volume
457.67K

Price performance

OMCL price history

1M range · 0 trading sessions · Daily adjusted prices

OMCL does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest OMCL news

The latest Smart Investors Daily articles mentioning OMCL.

Stock researchCompany · Overview

OMCL research

Overview

Company profile and research snapshot.

Company profile

Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$55.00
Implied upside
—
Analysts
—
OMCL recent ratings
DateFirmRatingTarget
Aug 3, 2026Piper SandlerOverweight—
Jul 31, 2026KeybancOverweight—
Jul 31, 2026Wells FargoOverweight—
Apr 29, 2026KeybancOverweight—
Apr 23, 2026Wells FargoOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 4, 2026

Omnicell (OMCL) Is Down 12.5% After Raising 2026 Revenue Outlook And Returning To Profitability

In the past quarter, Omnicell, Inc. reported second-quarter 2026 revenue of US$312.21 million and net income of US$24.29 million, with both basic and diluted earnings per share from continuing operations rising compared with a year earlier, and also showed improved profitability for the first half of 2026. Omnicell also raised its full-year 2026 revenue guidance to a range of US$1.23 billion to US$1.25 billion and projected third-quarter 2026 revenue of US$301 million to US$307 million,...

Yahoo · Aug 4, 2026

Omnicell (OMCL) Stock May Be 42% Below Fair Value On Weak Guidance

Omnicell stock is currently caught between two different valuation signals. The Discounted Cash Flow (DCF) estimate points to meaningful upside to intrinsic value, while market-based multiples suggest the shares already trade at a premium. Over the past 5 years Omnicell shareholders have seen the share price fall 77.6%, which sets a cautious backdrop for any claim that the stock now offers clear value. Recent product work at subsidiary EnlivenHealth, such as the VaxReach program to support...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By